Biosig shares soar on Ascendiant Capital target raise

Published 06/06/2025, 16:50
© Reuters.

Investing.com -- Shares of (NASDAQ:BSGM) surged 42.2% following a substantial analyst upgrade informed by the successful acquisition of Streamex Exchange Corp. Ascendiant Capital analyst Edward Woo has reiterated a Buy rating on BioSig Technologies Inc and raised the price target from $2.50 to $10.

BioSig’s recent merger with Streamex, a tokenization company focused on commodities, has been a key driver of the stock’s movement. The transaction, completed on May 28, resulted in Streamex becoming a wholly owned subsidiary of BioSig, with Streamex shareholders owning roughly 75% of BioSig’s fully diluted common stock pre-transaction. This merger introduces a new leadership team, with Henry McPhie, Co-Founder and CEO of Streamex, stepping in as the Chief Executive Officer of the combined entity.

The acquisition of Streamex is a significant pivot for BioSig, which had previously announced a major retrenchment on February 20, 2024, due to lack of capital. The retrenchment included terminating a significant number of employees and substantially reducing operations. Woo believes the merger marks a renewed direction for the company as it aims to secure new capital and leverage Streamex’s innovative technology in the commodity markets.

Streamex is poised to revolutionize commodity finance with its infrastructure that brings commodity markets onto the blockchain, offering enhanced liquidity, accessibility, and efficiency. The merger aligns with Streamex’s vision of bridging traditional finance with the digital economy, potentially unlocking new investment opportunities.

Despite the positive outlook presented by the merger, Ascendiant Capital has adjusted its EPS estimates for BioSig to $(0.25) from $(0.20) for fiscal year 2025, maintaining revenue estimates at approximately $0. The analyst notes that these estimates do not yet reflect the Streamex acquisition until more information about the combined company’s financials and outlook becomes available.

Woo believes that the market potential for Streamex presents high rewards for the risks involved and considers the current valuation of BioSig’s stock to be attractive. The substantial increase in the price target to $10.00 is based on a net present value (NPV) analysis, reflecting the analyst’s confidence in the significant upside potential balanced against the high risks.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.